PL354112A1 - Application of anti-ctla-4 antibodies - Google Patents

Application of anti-ctla-4 antibodies

Info

Publication number
PL354112A1
PL354112A1 PL02354112A PL35411202A PL354112A1 PL 354112 A1 PL354112 A1 PL 354112A1 PL 02354112 A PL02354112 A PL 02354112A PL 35411202 A PL35411202 A PL 35411202A PL 354112 A1 PL354112 A1 PL 354112A1
Authority
PL
Poland
Prior art keywords
ctla
antibodies
application
Prior art date
Application number
PL02354112A
Other languages
English (en)
Inventor
Douglas Charles Hanson
Eileen Elliot Mueller
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL354112A1 publication Critical patent/PL354112A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL02354112A 2001-05-23 2002-05-23 Application of anti-ctla-4 antibodies PL354112A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29304201P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
PL354112A1 true PL354112A1 (en) 2002-12-02

Family

ID=23127385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02354112A PL354112A1 (en) 2001-05-23 2002-05-23 Application of anti-ctla-4 antibodies

Country Status (14)

Country Link
US (1) US20030086930A1 (enExample)
EP (1) EP1262193A1 (enExample)
JP (1) JP2002371013A (enExample)
KR (1) KR100531707B1 (enExample)
CN (1) CN1404876A (enExample)
AU (1) AU4242102A (enExample)
CA (1) CA2382443A1 (enExample)
CZ (1) CZ20021760A3 (enExample)
HU (1) HUP0201737A2 (enExample)
IL (1) IL149701A0 (enExample)
MY (1) MY136095A (enExample)
PL (1) PL354112A1 (enExample)
SK (1) SK7242002A3 (enExample)
ZA (1) ZA200204020B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
WO2003086459A1 (en) * 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
TWI347951B (en) 2002-09-06 2011-09-01 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
WO2005010151A2 (en) 2003-06-27 2005-02-03 Abgenix, Inc Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
TWI353992B (en) 2003-07-22 2011-12-11 Schering Ag Rg1 antibodies and uses thereof
EP1660537A2 (en) * 2003-08-14 2006-05-31 Dyax Corp. Endotheliase-2 ligands
EP1515505A1 (en) * 2003-09-12 2005-03-16 Siemens Aktiengesellschaft Reachability maintainance of a moving network based on temporary name identifiers
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
CA2560919A1 (en) * 2004-03-26 2005-10-06 Pfizer Products Inc. Uses of anti-ctla-4 antibodies
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
MX2007003804A (es) * 2004-11-04 2007-04-23 Pfizer Prod Inc Tratamiento combinado de anticuerpo anti-ctla4 e inhibidor de aromatasa para el cancer de mama.
US20090110681A1 (en) 2005-03-08 2009-04-30 Pfizer, Inc. Anti-M-CSF Antibody Compositions
EP1863532A1 (en) * 2005-03-23 2007-12-12 Pfizer Products Incorporated Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
AR053690A1 (es) * 2005-03-23 2007-05-16 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal
CA2970873C (en) * 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
MX351401B (es) 2005-06-08 2017-10-13 Dana Farber Cancer Inst Inc Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
CN101268101A (zh) * 2005-07-07 2008-09-17 科利制药集团公司 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
WO2007067959A2 (en) 2005-12-07 2007-06-14 Medarex, Inc. Ctla-4 antibody dosage escalation regimens
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CA2694034A1 (en) * 2007-07-27 2009-02-05 Pfizer Limited Antibody purification process by precipitation
AU2008307643B9 (en) 2007-09-28 2014-04-17 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
RU2373836C2 (ru) * 2007-12-18 2009-11-27 Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
EP2227296B1 (en) * 2008-01-08 2015-11-25 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CN102822200A (zh) * 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
RU2421217C2 (ru) * 2009-09-03 2011-06-20 Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
ES2724801T3 (es) 2011-04-19 2019-09-16 Pfizer Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
DK3011974T3 (en) 2011-06-02 2018-11-12 Univ Louisville Res Found Inc Anti-nucleolin agent-conjugated nanoparticles
EP3553083A1 (en) 2012-03-13 2019-10-16 F. Hoffmann-La Roche AG Combination therapy for the treatment of ovarian cancer
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
EP3494996A1 (en) * 2012-08-23 2019-06-12 Agensys, Inc. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
DK2925350T3 (da) * 2012-12-03 2019-05-13 Bristol Myers Squibb Co Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
HUE046964T2 (hu) 2013-08-08 2020-04-28 Cytune Pharma Kombinált gyógyászati készítmény
DK3444271T3 (da) 2013-08-08 2022-01-10 Cytune Pharma Il-15- og il-15r-alfa-sushi-domænebaserede modulokiner
CN105636986B (zh) * 2013-10-18 2020-05-12 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
US12427173B2 (en) * 2014-03-31 2025-09-30 Biomed Valley Discoveries, Inc. Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
KR20170002403A (ko) * 2014-05-01 2017-01-06 가부시키가이샤 아네로파마·사이엔스 이종 폴리펩티드 발현 카세트
IL293212B2 (en) 2014-05-28 2023-12-01 Memorial Sloan Kettering Cancer Center Anti-GITR antibodies and methods of using them
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
ES2727137T3 (es) 2014-08-28 2019-10-14 Halozyme Inc Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CA3126536C (en) 2014-10-14 2023-07-25 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
HRP20210200T1 (hr) 2014-12-31 2021-04-02 Checkmate Pharmaceuticals, Inc. Kombinirana antitumorska imunoterapija
ES2882157T3 (es) * 2015-02-13 2021-12-01 Sorrento Therapeutics Inc Productos terapéuticos de anticuerpos que se unen a CTLA4
EP3291839A1 (en) 2015-05-05 2018-03-14 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
DK3303394T3 (da) * 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
TWI733687B (zh) * 2015-07-22 2021-07-21 美商索倫多醫療公司 結合ｌａｇ３之抗體治療劑
JP2018523712A (ja) * 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
EP3433275A1 (en) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
EA039322B1 (ru) * 2016-04-15 2022-01-13 Эйдженус Инк. Антитела против ctla-4 и способы их применения
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
EP3505183B1 (en) * 2016-08-26 2022-03-30 Tetsuji Okuno Microvascular blood flow decreasing agent and use thereof
WO2018106864A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
PT3551660T (pt) * 2016-12-07 2023-11-30 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
AU2019214865B2 (en) 2018-02-02 2025-04-10 OncoC4, Inc. Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
WO2019179388A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-ctla-4 antibody polypeptide
AU2019251421B2 (en) 2018-04-09 2025-05-01 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
CN112673092B (zh) 2018-07-11 2024-03-29 阿克蒂姆治疗有限公司 工程化的免疫刺激性细菌菌株及其用途
CN110092826B (zh) * 2019-02-28 2022-04-15 天津大学 CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
WO2021238932A1 (zh) * 2020-05-26 2021-12-02 百奥泰生物制药股份有限公司 多特异性抗体及其应用
WO2022010537A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Gas41 inhibitors and methods of use thereof
WO2022086852A2 (en) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
EP4326321A1 (en) 2021-04-20 2024-02-28 Institut Curie Compositions and methods for use in immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
SI1141028T1 (sl) * 1998-12-23 2010-05-31 Pfizer Človeška monoklonska protitelesa proti CTLA
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP4093757B2 (ja) * 1999-08-24 2008-06-04 メダレックス， インコーポレイテッド ヒトｃｔｌａ−４抗体およびその使用
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules

Also Published As

Publication number Publication date
ZA200204020B (en) 2003-11-21
HUP0201737A2 (hu) 2003-02-28
IL149701A0 (en) 2002-11-10
US20030086930A1 (en) 2003-05-08
MY136095A (en) 2008-08-29
JP2002371013A (ja) 2002-12-26
CN1404876A (zh) 2003-03-26
KR20020090873A (ko) 2002-12-05
CA2382443A1 (en) 2002-11-23
AU4242102A (en) 2002-11-28
KR100531707B1 (ko) 2005-11-30
CZ20021760A3 (cs) 2003-05-14
EP1262193A1 (en) 2002-12-04
HU0201737D0 (enExample) 2002-07-29
SK7242002A3 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
PL354112A1 (en) Application of anti-ctla-4 antibodies
HUP0402164A3 (en) Polycistronic expression of antibodies
IL212419A0 (en) Methods of administering anti-tnf antibodies
EP1432444A4 (en) ANTI-BETA ANTIBODIES
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
IL175935A0 (en) Solid forms of anti-egfr antibodies
IL166244A0 (en) Super humanized antibodies
HU230006B1 (en) Antagonistic anti-htnfsf13b human antibodies
EP1441765A4 (en) PROCESS FOR THE PREPARATION OF MONOCATENARY ANTIBODIES
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
AU2002365649A8 (en) Anti-dota antibody
GB0126378D0 (en) Antigen
EP1455822A4 (en) LYOPHILIZED MONOCLONAL ANTIBODY COMPOSITIONS
AU2002242447A1 (en) Use of polyclonal immunoglobulins
EP1446416A4 (en) TUMOR-SPECIFIC MONOCLONAL ANTIBODIES
ZA200508071B (en) Polycistronic expression of antibodies
GB0121727D0 (en) Monoclonal antibodies
GB0119553D0 (en) Antibodies
GB0118696D0 (en) Novel antibodies
GB0120494D0 (en) Novel antibody
AU2002211364A1 (en) Human anti-cd40 antibodies
GB0119004D0 (en) Antibody

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)